Market Insight- Global Lactulose Concentrate Market Overview 2025
Global Lactulose Concentrate Market Was Valued at USD 158.34 Million in 2024 and is Expected to Reach USD 210.32 Million by the End of 2035, Growing at a CAGR of 2.50% Between 2025 and 2035.– Bossonresearch.com
Lactulose concentrate is a synthetic disaccharide composed of fructose and galactose, primarily used as a pharmaceutical and functional food ingredient. As a non-digestible sugar, it reaches the colon intact, where it is metabolized by gut microbiota to produce short-chain fatty acids and lower colonic pH, thereby stimulating bowel movements and aiding in the management of constipation, hepatic encephalopathy, and other gastrointestinal disorders. Beyond its therapeutic applications, lactulose concentrate is also employed in the food and beverage industry as a prebiotic to promote gut health. Its solubility, low glycemic index, and functional properties make it suitable for liquid formulations, syrups, and dietary supplements, serving both medical and consumer wellness markets.
The lactulose concentrate market is undergoing significant expansion and transformation, driven by increasing clinical recognition, technological innovation, and evolving market dynamics. Growing research demonstrates lactulose’s broad potential in gut health, immune regulation, metabolic modulation, and chronic disease management, highlighting its rising importance in pharmaceuticals, functional foods, and animal nutrition. In China, surging demand has prompted manufacturers such as Jiangxi Dankang, Hubei Guangchen, Baolingbao, and Hunan Baolishi to expand capacity, intensifying competition and reshaping market structure. Meanwhile, biological production methods, particularly enzymatic conversion using cellobiose 2-epimerase (CE) and high-cell-density fermentation, are gaining attention for higher product purity, environmental sustainability, and operational efficiency, despite technical limitations. Digital transformation and AI integration are further influencing the market, with short-video platforms enhancing brand IP and AI tools optimizing production efficiency and supporting sustainable practices.
By 2024, the global lactulose concentrate market reached USD 158.34 million and is projected to expand at a CAGR of 2.50% from 2025 to 2035, reaching USD 210.32 million. Market growth is primarily driven by demand in pharmaceuticals, functional foods, and infant nutrition. Rising global health awareness and increasing chronic disease prevalence, particularly in Asia-Pacific, have strengthened lactulose’s position as a key therapeutic for constipation, hepatic encephalopathy, and gut microbiota disorders. Population aging provides a stable, long-term demand foundation, as elderly consumers increasingly seek products that support gastrointestinal health. Rising attention to maternal and infant nutrition, the growth of prebiotics and functional foods, and improved healthcare infrastructure in emerging markets such as China and India further expand market potential.
Nevertheless, the market faces interconnected challenges. Demand remains sensitive to economic fluctuations; while medical demand for constipation and hepatic encephalopathy is stable, the functional food and consumer wellness segments are vulnerable to economic slowdowns, especially in emerging markets where reduced purchasing power increases price sensitivity. Intensifying global competition among multinational and local players elevates price pressures and necessitates continuous innovation, efficiency improvements, and strict quality control.
Segment-wise, chemical synthesis currently dominates the market, accounting for 84.37% of revenue in 2024, whereas enzymatic production, though smaller at 15.63%, is expected to grow rapidly with a CAGR of 8.59% from 2025 to 2033, reflecting a strong market shift toward biologically driven processes due to higher product purity, milder reaction conditions, and alignment with sustainability trends. By application, the pharmaceutical sector leads with a 76.01% market share in 2024, reflecting lactulose’s primary use in managing constipation and hepatic encephalopathy. The food industry is also growing steadily, with a CAGR of 3.07%, driven by lactulose’s use as a prebiotic and functional ingredient in processed foods and weight management products.
Geographically, the Asia-Pacific region dominates the market, capturing 48.00% of revenue in 2024, fueled by a large population, growing health awareness, and increasing applications across pharmaceuticals, functional foods, and infant nutrition. It is also projected to maintain the fastest growth with a CAGR of 3.09% from 2025 to 2033, underscoring its role as the primary driver of market expansion. North America and Europe hold significant shares of 24.92% and 19.23%, respectively, supported by high prevalence of chronic constipation, though their growth rates are more moderate at 1.53% and 1.77%.
Lactulose Concentrate Industry Chain Analysis
Preparation Method
(1) Chemical Catalysis Method
The chemical catalysis method is currently the only industrial method for producing Lactulose. This process mainly relies on the Lobry-de Bruyn-van Ekenstein transformation under strongly alkaline conditions, which converts the glucose moiety in lactose into a fructose moiety, thereby forming Lactulose. Commonly used alkalis include calcium hydroxide, sodium hydroxide, potassium hydroxide, boric acid, sodium aluminate, tertiary amines (such as triethylamine), sulfite solutions, and phosphate solutions. In addition, alkaline substances such as sepiolite, calcium carbonate, and eggshells also exhibit catalytic activity.
Although there are many types of catalysts, each has its own advantages and disadvantages. For example, the conversion rate with slaked lime (calcium hydroxide) is relatively low, generally not exceeding 30%. Boric acid and sodium aluminate can achieve higher conversion rates (75–85%), but they leave a large amount of boron or aluminum ions and require significant acid consumption for neutralization. Removing these ions typically requires expensive specialty resins, which presents challenges for industrial-scale production. Therefore, current industrial production still largely relies on lower-conversion catalysts such as sodium hydroxide or calcium hydroxide.
The chemical reaction process is generally divided into three stages. The first stage is characterized by rapid Lactulose formation. The second stage involves sugar decomposition and byproduct formation, accompanied by a drop in pH and minor additional Lactulose generation. The third stage is the pigment formation stage, during which the pH approaches neutral. Analysis of the reaction products shows that D-galactose is a common byproduct, mainly originating from the decomposition of lactose and Lactulose.
Since sugars undergo browning reactions under strongly alkaline conditions, the chemical method usually produces pigments. Decolorization is generally achieved using activated carbon or decolorizing resins, resulting in a Lactulose solution that is pale yellow to yellow. In addition to decolorization, desalting is also an essential step in the chemical method, typically achieved using ion exchange resins.
(2) Differential Epimerase Method
Differential epimerization widely occurs in sugars—for example, D-glucose can be converted to D-mannose, and D-fructose to D-psicose. Enzymes that catalyze these reactions can also possess aldose–ketose isomerization activity. For instance, cellobiose 2-epimerase (CE enzyme, EC 5.1.3.11) can epimerize lactose to produce epilactose and also isomerize lactose to produce Lactulose.
(3) β-Galactosidase Method
β-Galactosidase, also known as lactase (EC 3.2.1.23), is an enzyme capable of hydrolyzing lactose into D-glucose and D-galactose. It also exhibits transglycosylation activity, enabling the synthesis of oligosaccharides such as galactooligosaccharides. The β-galactosidase method was the first discovered enzymatic method for producing Lactulose. This method uses lactose and D-fructose as dual substrates. The transglycosylation activity of β-galactosidase releases one molecule of D-glucose, while the remaining galactose moiety condenses with D-fructose to form Lactulose.
The final reaction mixture typically includes Lactulose, D-glucose, D-galactose, residual D-fructose, and lactose. The generation of D-galactose and part of D-glucose results from the hydrolytic activity of the enzyme, which causes lactose decomposition. Because the transglycosylation activity of β-galactosidase is weaker than its hydrolytic activity, the Lactulose yield of this method is relatively low. Furthermore, product separation and purification are challenging, limiting its industrial potential.
In summary, lactulose can be produced through either chemical synthesis or enzymatic methods. Chemical methods have low conversion rates, but the catalysts used are inexpensive (although required in large quantities) and easy to operate, making them the mainstream production method currently, and this is expected to remain so for some time. The β-galactosidase method has low conversion efficiency and limited practical value. In comparison, the cellobiose differential epimerase method shows greater potential, with its main bottlenecks being the control of the epilactose byproduct content and relatively low enzymatic activity. When the cost of enzymatic methods approaches or falls below that of chemical methods, the enzymatic approach is expected to completely replace chemical synthesis due to its environmental advantages and higher product quality.
The total production cost of lactulose concentrate typically comprises five primary components — raw materials, energy, labor, logistics, and overhead. While the exact proportions vary by production route (fermentation or synthesis) and regional operational environment, the following provides a representative breakdown:
Table Manufacturing Cost Analysis
|
Cost Component |
Description |
Estimated Share of Total Cost |
Key Influencing Factors |
|
Raw Materials |
Lactose (pharma/food grade), catalysts (NaOH, borohydride or enzymes), purification aids, enzymes |
50–60% |
Price volatility of lactose, enzyme costs, and chemical reagent prices. |
|
Energy |
Electricity, steam, cooling water for isomerization, evaporation, crystallization, drying |
10–15% |
Local energy tariffs, process efficiency, and production scale. |
|
Labor |
Operators, quality control, maintenance staff |
8–14% |
Workforce efficiency, automation level, and regional wage standards. |
|
Logistics and Distribution |
Packaging, transportation, and warehousing |
5–8% |
Distance to suppliers and markets, fuel costs, and shipping infrastructure. |
|
Overhead and Operational Costs |
Depreciation, plant maintenance, quality assurance, waste treatment, regulatory compliance, R&D amortization |
15-25% |
Plant scale, MP/pharma certification level, maintenance efficiency, regulatory requirements, and management practices. |
Key Development Trends
Research Results Drive Market Diversification
Lactulose, a non-absorbable disaccharide, has been extensively explored in numerous clinical and experimental studies in recent years, demonstrating its potential in gut health, immune regulation, metabolic modulation, and the treatment of various diseases. Initially synthesized by Montgomery and Hudson in 1929, lactulose’s prebiotic properties were first discovered by Petuely and Mayerhofer in 1957. Since then, it has been widely used in treating conditions such as constipation, hepatic encephalopathy (HE), and gut dysbiosis. Further research, including work by Panesar and Kumari (2011), confirmed that lactulose promotes the growth of beneficial bacteria such as bifidobacteria, thereby regulating gut microbiota structure and function, making it an effective support agent for intestinal health.
Clinically, lactulose’s role in treating constipation and hepatic encephalopathy has gained broad recognition. For instance, Balzano (2023) reviewed lactulose’s clinical effectiveness in hepatic encephalopathy treatment, noting that lactulose reduces intestinal ammonia production, alleviates symptoms, and significantly lowers mortality rates. Additionally, a randomized controlled trial by Wang et al. (2023) demonstrated lactulose’s ability to improve gut function and promote short-chain fatty acid production in patients with acute pancreatitis and intestinal dysfunction, further supporting its potential in treating various diseases.
Lactulose’s benefits extend beyond gut health into immune function and the management of inflammatory bowel diseases (IBD). Karakan et al. (2021) showed that lactulose inhibits the growth of pathogenic bacteria, maintains gut microecology, and reduces the incidence of urinary tract and respiratory infections, enhancing overall immunity. Furthermore, lactulose has proven effective in reducing intestinal inflammation and promoting mineral absorption, including calcium, magnesium, zinc, and iron, through its short-chain fatty acid (SCFA) effects on intestinal acidification.
In animal nutrition, Elkomy et al. (2023) found that lactulose significantly improved egg production, egg quality, and overall performance in laying hens, while also enhancing gut function, increasing villus length, and promoting digestive enzyme activity. This study offers new insights into lactulose’s application in poultry farming, especially as an antibiotic-free feeding alternative.
As more research findings are published, lactulose’s broad application potential is increasingly recognized. Whether in gut health, immune function, metabolic disease management, or the food and animal nutrition sectors, lactulose’s prebiotic role is gaining greater acknowledgment among researchers.
Expansion of Lactulose Concentrate Production Capacity in China
As demand for lactulose increases in China, several companies are actively expanding their production capacities. In recent years, particularly in the pharmaceutical and health supplement sectors, demand for lactulose has steadily risen, prompting companies to invest in expanding production capabilities. Specifically, companies such as Jiangxi Dankang Pharmaceutical, Hubei Guangchen Pharmaceutical, Baolingbao, and Hunan Baolishi have announced plans for large-scale lactulose production expansions.
For example, Jiangxi Dankang Pharmaceutical is undertaking a technological transformation of its lactulose concentrate production line, with a planned investment of 30 million RMB. This project will eliminate outdated equipment and implement digital transformation, boosting annual production capacity to 6,000 tons. Hubei Guangchen Pharmaceutical is investing 25 million RMB to establish a new lactulose production line at its existing facility, aiming for an annual production capacity of 2,000 tons upon completion. Hunan Baolishi plans to invest 62 million RMB to expand multiple production lines, including lactulose, with an annual output of 500 tons. Baolingbao is also advancing a strategic partnership with Beijing Fengli Pharmaceutical, working on the approval process for lactulose concentrate. This collaboration is expected to strengthen Baolingbao's competitive position in the domestic market. Additionally, Hebei Jiheng Pharmaceutical and other companies have announced similar capacity expansion plans. With more companies entering the market, China’s lactulose concentrate market will experience intense competition and a market reshuffling period in the coming years.
Biological Production Method Shows Growing Potential
Lactulose's traditional production methods rely heavily on chemical processes. While these methods meet basic market demands, they face several challenges, including the production of byproducts, high costs, environmental pollution, and difficulties in controlling product purity, especially in pharmaceutical-grade products. These limitations have hindered lactulose’s broader application in various sectors. To address these issues, biological production methods for lactulose have emerged as a promising alternative. These methods, especially in terms of environmental friendliness, efficiency, and cost advantages, represent a sustainable solution for production.
The key enzyme in the biological production of lactulose is cellobiose 2-epimerase (CE). CE can efficiently catalyze the conversion of lactose into lactulose, offering fewer byproducts and higher conversion efficiency compared to traditional chemical methods. However, the current CE enzymes still face technical challenges, such as insufficient enzyme activity and poor stability, which limit their application in industrial-scale production. These issues need to be addressed through technological breakthroughs to support large-scale industrial production.
The industrial potential of CE is being continuously explored. In traditional biological production, lactose serves as the substrate. However, earlier β-galactosidase catalytic methods faced low conversion rates and required the addition of D-fructose as a secondary substrate, making the process complex and complicating product separation. The application of CE greatly simplifies this process, directly converting lactose into lactulose without the need for a second substrate, and offering higher conversion rates. With the advancement of biotechnology, particularly with AI-supported synthetic biology technologies, companies like Xinbeilai have developed next-generation CE variants, such as CE S+.
Additionally, high cell-density fermentation (HCDC) technology is providing technical support for CE enzyme industrialization. By increasing the microbial host’s cell density, more recombinant enzymes can be produced, reducing production costs and improving efficiency. Although research on CE enzymes in this area is still incomplete, further development in fermentation process control is expected to enhance the efficiency and economic viability of biological lactulose production.
Driving Factors
Rising Health Awareness and Increasing Chronic Disease Incidence
The global rise in health awareness and the increasing prevalence of chronic diseases, especially in the Asia-Pacific region, are becoming key factors driving the demand for lactulose. The high incidence of chronic conditions such as diabetes, liver diseases, and constipation has led to increased demand for lactulose as a therapeutic agent and a key ingredient in health supplements.
Population aging, particularly the severe aging trends in East Asia, represents the most stable and enduring driver for the lactulose concentrate market. According to United Nations projections, by the late 2070s, the global population aged 65 and older is expected to reach 2.2 billion, surpassing the number of children under 18. By the mid-2030s, the population aged 80 and above will reach 265 million, exceeding the number of infants. The elderly population tends to suffer from poor gastrointestinal motility, gut microbiome imbalances, and higher rates of constipation, which leads to a consistent demand for products that improve gut function. Lactulose, as a first-line treatment for chronic constipation, is directly benefiting from the aging global population, which drives the demand for corresponding formulations and, subsequently, the consumption of lactulose concentrate.
The high prevalence of liver diseases, particularly the treatment needs for severe complications like hepatic encephalopathy, also provides a solid market foundation for lactulose. According to a 2022 study by the International Agency for Research on Cancer (IARC), the global number of liver cancer diagnoses and related deaths is expected to increase by more than 55% by 2040. Clinical data shows that 30-40% of liver cancer patients develop significant hepatic encephalopathy, while up to 70% of liver tumor patients experience varying degrees of hepatic encephalopathy symptoms. This trend has driven the continuous expansion of the lactulose formulation market, with lactulose remaining one of the primary drugs for treating hepatic encephalopathy.
Upgrading Maternal and Infant Nutrition
The significant increase in demand for functional additives in infant formula is one of the key drivers for the expansion of the lactulose concentrate market. As nutritional standards for infants continue to improve, such as the implementation of China’s new national standards for infant formula, which stipulates that lactose must constitute at least 90% of carbohydrates in infant formula for babies aged 6-12 months, the demand for lactose and its derivatives has been strongly encouraged by policy.
In this context, lactulose, as a high-quality prebiotic, has seen its proportion in infant formula steadily increase. Lactulose effectively promotes the proliferation of beneficial gut bacteria, improving the intestinal health of infants, and has thus become an important functional additive in infant formula. In addition to infant foods, products specifically designed for children's nutrition have also shown good market prospects due to the growing demand for child nutrition.
The Rise of Prebiotics and Functional Foods
Lactulose, as a key prebiotic, is no longer confined to the pharmaceutical industry but is gradually expanding into the functional food sector. With increasing consumer awareness of gut health, the demand for prebiotics is rapidly growing. Lactulose’s ability to stimulate the growth of beneficial gut bacteria, such as bifidobacteria, has made it an essential ingredient in prebiotic foods and dietary supplements. Currently, the application of lactulose in the prebiotic sector is not limited to treating constipation but also includes the prevention and improvement of various gut health issues, further driving its use in health supplements and functional foods.
In the food industry, the range of applications for lactulose is expanding quickly. With the "sugar reduction, not sweetness reduction" trend, lactulose is being widely used in products like candies and baked goods to meet the market's strong demand for low-sugar foods. Especially in new food product development, lactulose is regarded as an ideal alternative sweetener. Its dual role as a sugar substitute and a promoter of gut health has accelerated its adoption in candies, beverages, and baked goods.
This market trend further enhances lactulose’s functional ingredient properties. In the past, lactulose mainly relied on demand from the pharmaceutical industry, but with changing health consumption concepts, lactulose is transitioning from a traditional therapeutic drug to a functional ingredient with a broader market outlook.
Global Lactulose Concentrate Market: Competitive Landscape
The global lactulose concentrate market exhibits moderate concentration. In 2024, the top five manufacturers accounted for 59.51% of the market (CR5), with Abbott as the leading producer at 19.30%, followed by Fresenius Kabi Austria GmbH at 13.28%. The Herfindahl-Hirschman Index (HHI) of 7.94% confirms a moderately concentrated market, indicating that while a few major companies dominate, smaller producers still have substantial competitive opportunities. Key market participants include Abbott, Fresenius Kabi Austria GmbH, Morinaga, Illovo Sugar, Lactitol India Private Limited (LIPL), Merro Pharmaceutical, Lactose (India) Limited, Solactis, Hubei Guangchen Pharmaceutical, Biofac AS, Jiangsu Hanstone Pharmaceutical, Dandong Kangfu, Sanes Pharmaceuticals, and Syngars Technology Co Ltd.
Key players in the Lactulose Concentrate Market include:
Fresenius Kabi Austria GmbH
Morinaga
Illovo Sugar
Lactitol India Private Limited (LIPL)
Merro pharmaceutical
Lactose (India) Limited
Solactis
Hubei Guangchen Pharmaceutical
Biofac AS
Jiangsu Hanstone Pharmaceutical
Dandong Kangfu
Sanes Pharmaceuticals
Syngars Technology Co Ltd
Others
Request for more information
Click to view the full report TOC, figure and tables: https://bossonresearch.com/productinfo/1547548.html
About US:
Bosson Research (BSR) is a leading market research and consulting company, provides market intelligence, advisory service and market research reports for the automobile, electronics and semiconductor, and consumer good industry. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Bosson Research provides one-stop solution right from data collection to investment advice. The analysts at Bosson Research (BSR) dig out factors that help clients understand the significance and impact of market dynamics. Bosson Research (BSR) bring together the deepest intelligence across the widest set of capital-intensive industries and markets. By connecting data across variables, our analysts and industry specialists present our customers with a richer, highly integrated view of their world.
Contact US:
Tel: +86 400-166-9288
E-mail: sales@bossonresearch.com
